STD Comprehensive Package (DO NOT USE)

We are required to report positive results for this test to the CDC.


Fasting Required: No

Specimen: Blood

Results: 3-5 Business Days
Note: Result turn around times are an estimate and are not guaranteed. Our reference lab may need additional time due to weather, holidays, confirmation/repeat testing, or equipment maintenance.

Tests Included:

Chlamydia/Gonorrhea: Clamydia trachomatis and Neisseria gonorrhoeae are the most common sexually-transmitted diseases. In 2002, the Centers for Disease Control and Prevention published guidlines for laboratory testing that emphasized the use of nucleic acid amplification tests for screening for Chlamydia trachomatis and also for Neisseria gonorrhoeae when conditions of transport could compromise viability of the organism.1,2 Other guidelines have recommended Chlamydia screening for all women 15-25, as well as testing pregnant women during their first trimester for both Chlamydia and Neisseria. In some settings, the fact that both Neisseria and Chlamydia testing can be performed on the same specimen testing for both can be an effective strategy.

RPR Qualitative: The test is looking for evidence of Treponema pallidum, the bacterium that causes syphilis. Syphilis is a common sexually transmitted disease. It is easily treated but can cause severe health problems if left untreated.

HIV 1: Human immunodeficiency virus (HIV 1/O/2), the etiologic agent of the acquired immunodeficiency syndrome (AIDS) is a cytopathic retrovirus. This test uses recombinant antigen sources and detects antibodies by specific immune binding and subsequent chemiluminescent reaction (ICMA technology). Sensitivity and specificity of this assay are 100% and 99.9% respectively. Sera which are repeatedly reactive in two out of three tests are subject to confirmatory HIV-1 testing by the Western blot method. Some individuals may be initially reactive by the preliminary test and negative or indeterminate by Western blot. This may be caused by other viral antibodies or autoantibodies which cross react with the viral antigens although this is rare.

HSV I&II: Detect herpes simplex I and II DNA in clinical specimens; when performed on cerebrospinal fluid, supports a diagnosis of herpes simplex encephalitis and herpes simplex meningitis

Hepatitis A Antibody IgM: Hepatitis A virus is a picornavirus, and antibody is made to capsid proteins. Fecal excretion of HAV peaks before symptoms develop. If hepatitis A antibody is IgM, the hepatitis A infection is probably acute. IgM antibody develops within a week of symptom onset, peaks in 3 months, and is usually gone after 6 months. Hepatitis A antibody of IgG type is indicative of old infection, is found in almost 50% of adults and is not usually clinically relevant. Many cases of hepatitis A are subclinical, particularly in children. Presence of IgG antibody to HAV does not exclude acute hepatitis B or other forms of hepatitis.

Hepatitis B Core Antibody IgM: Differential diagnosis of hepatitis; also used in conjunction with other B viral serologic markers, to assess the stage of hepatitis B infection. At times this may be the only demonstrable marker for the diagnosis of current or past hepatitis B viral infection.

Hepatitis B Surface Antigen: Hepatitis B virus (HBV) is a DNA virus with a protein coat, the surface antigen (HBsAg) and a nucleic acid core, the core antigen (HBcAg). There are eight different serotypes. Early in infection, HBsAg, HBV DNA, and DNA polymerase can all be detected in serum.
HBsAg can be detected 1-7 weeks before liver enzyme elevation or the appearance of clinical symptoms. Three weeks after the onset of acute hepatitis, about 50% of patients will still be positive for HBsAg, while at 17 weeks only 10% are positive. The best available markers for infectivity are HBsAg and HBeAg. The presence of anti-HBs is frequently associated with noninfectivity. The chronic carrier state is indicated by the persistence of HBsAg and/or HBeAg over long periods (6 months to years) without seroconversion to the corresponding antibodies. Such a condition has the potential to lead to serious liver damage, but may be an isolated asymptomatic serologic phenomenon.
Persistence of HBsAg, without anti-HBs, with combinations of positivity of anti-HBc, HBeAg, or anti-HBe indicates infectivity and need for investigation for chronic persistent or chronic aggressive hepatitis.

Hepatitis C Antibody: Following the development of sensitive and specific testing for hepatitis B, 90% of post-transfusion hepatitis is now hepatitis C. A gene product (c100) of hepatitis C virus (HCV) was isolated and an assay for anti-HCV developed. The assay detects antibody to a presumptive togavirus or flavivirus which may be an etiologic agent of non-A, non-B hepatitis (which may not be a unitary disease entity).
For blood donors, hepatitis C serology correlates with surrogate tests for non-A, non-B hepatitis (ALT and anti-HBc). Since hepatitis C serology identifies a broader group of infected individuals than surrogate testing, it reduces risk of HCV during transfusion. Studies in hemophiliacs indicate that antibody to HCV is a reliable marker of HCV.